Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Beam Therapeutics ( (BEAM) ) has issued an announcement.
Beam Therapeutics announced advancements in its base editing portfolio with key milestones anticipated in 2025. This progress is expected to bolster its industry positioning by advancing clinical programs, which aim to deliver life-long, curative genetic medicines, potentially impacting stakeholders through enhanced therapeutic options and financial stability.
More about Beam Therapeutics
Beam Therapeutics operates in the biotechnology industry, specializing in precision genetic medicines using base editing technology. The company focuses on developing therapies for rare and common diseases, including sickle cell disease, alpha-1 antitrypsin deficiency, and glycogen storage disease, with a platform capable of rapidly programmable precision medicines.
YTD Price Performance: 6.84%
Average Trading Volume: 1,200,954
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $2.19B
For a thorough assessment of BEAM stock, go to TipRanks’ Stock Analysis page.
